What is the NOCEDP?

The NOCEDP is a clinical research program designed to identify those women who are at increased risk for
developing ovarian cancer and to apply new research and tests, related to the ovaries,
to help detect ovarian cancer at an early stage.

The program combines the expertise of gynecologic oncology, medical oncology, advanced-practice oncology nursing,
 genetics, ultrasonography, biochemistry, and molecular biology to offer a comprehensive
 early detection program for women at risk of developing ovarian cancer.

If you wish to participate in the program or want further information, call Dr. Fishman, 212-241-1901
NOCEDP is located at Mount Sinai School of Medicine.

Remember! September is Ovarian Awareness Month.

Letter from Dr. Fishman

Dear VOICE Supporters:
The National Ovarian Cancer Early Detection Program (NOCEDP) is a multi-disciplinary international collaboration between
over 200 physicians and the scientists committed to the development of novel methods for the accurate detection of early rather
than advanced stage epithelial ovarian cancer.  As such, this makes the NOCEDP perhaps the larges integrated multi disciplinary program of clinicians, scientists and institutions ever, unifying to improve women's health care.  A detailed knowledge of genetics
and the specific molecular and biochemical interactions that regulate ovarian carcinogens, invasion and metastasis have translated
into the creation of novel imaging techniques and identification of potential biomarkers to achieve this goal.  Not only do we
identify those women at high risk, but also offer them and their families a comprehensive multi-disciplinary program which
combines expertise in clinical medicine and basic science to optimize those individuals health care.  Our aim is to decrease the morbidity and mortality associated with ovarian cancer.  Thank you for supporting VOICE and what it stands for.

______________________________________________________________________________


Statistics for Ovarian Cancer:

- Approximately 24,000 women are diagnosed annually
- About 75% are diagnosed after the disease has spread (stages III and IV)
- 5 Year survial rate (due to late detection) has previously been 15% and is now approaching 25%
- Cases with an early diagnosis (stage I) have an overall 5 year survial rate approaching 90%

Symptoms of Ovarian Cancer:

- Fatigue
- Constant feeling of fullness + bloating
- Pelvic and/or abdominal pain and discomfort
- Pain during intercourse
- Abnormal or postmenopausal bleeding
- Unexplained weight loss or gain
- Unexplained change in bowel and/or bladder habits
- Gastrointestinal upset such as gas, indigestion or nausea

These symptoms and potential signs of ovarian cancer are vague or "silent". 
Only about 10% of these cancers are found in the early stages.

TO PARTICIPATE IN THE NATIONAL OVARIAN CANCER EARLY DETECTION PROGRAM, which is
designed to identify those women who are at risk for developing ovarian cancer and to apply new research and tests to the
ovaries, to help detect ovarian cancer at an early and treatable stage, call (212)241-1901 , (Doctor Fishman)
at the Mt Sinai School of Medicine. 

Tell them that you heard about them through VOICE, the Varadi Ovarian Initiative for Cancer Education.